

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

FEB 2 6 2002

Gordon A. Wong, M.D. Vortran Medical Technology 1, Inc. 3941 J St., Suite 354 Sacramento, CA 95819-3633

Re:

K982016

Piper IPPBTM Model 2055 Regulation Number: 868.5905

Regulation Name: Noncontinuous Ventilator

Regulatory Class: II (two) Product Code: 73 NHJ

Dear Dr. Wong:

This letter corrects our substantially equivalent letter of November 3, 1998, regarding the Piper IPPBTM Model 2055. Our letter identified the product code as 73 BZD. This is in error; the correct product code is 73 NHJ as indicated above.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for <u>in vitro</u> diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Bram D. Zuckerman, M.D.

Acting Director

Division of Cardiovascular and

Respiratory Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

Page <u>1</u> of <u>1</u>

510(k) Number (if know	vn):	K982016		
) 10(K) Humoor (11 1211)	, rr	ACCOMPANY OF THE STATE OF THE S	Lating a 120 De Nicola Comp	
Device Name: <u>I</u>	Piper II	JB.m.		
Indication for Use:				
			it positive pressure	
aerosol treatn	nent of	n patients w	ith a body weight	·
greater than 3	0 kg (a			
(PLEASE DO NOT WRI PAGE IF NEEDED)	ITE BEL	OW THIS LINI	E CONTINUE ON ANOTHE	R
Concurrence Mark Ki	1 -		Device Evaluation (ODE)	
Prescription Use: (Per 21 CFR 810.109)		OR	Over-the-Counter Use	
(Division Sign-Off) Division of Cardiovascul and Neurological Device		atory,		
510(k) Number				
	85 = 2 5 6 3 45 - 72 8 9		(Optional Forma	it 1-2-96)
IPK2-IU.DOC				

 Foundation (Children and According Children and According (IAC) (MAC)



Page $\underline{1}$ of $\underline{1}$

510(k) Number (if known): <u>K98201</u>				
Device Name: Piper IPPB TM				
Indication for Use:				
For use in delivering intermittent positive pressure aerosol treatment on patients with a body weight greater than 30 kg (adults).				
(PLEASE DO NOT WRITE BELOW THIS LINE CONTINUE ON ANOTHER PAGE IF NEEDED)				
Concurrence of CDRH, Office of Device Evaluation (ODE)				
Prescription Use: OR Over-the-Counter Use (Per 21 CFR 810.109)				
(Division Sign-Off) Division of Cardiovascular, Respiratory, and Neurological Devices 510(k) Number				
(Optional Format 1-2-96) IPK2-IU.DOC				

2000 Laterett, State 2601 2 (1) 36000, Julio Wij 2 (30) (10) California (2) (17) (1 20) 733 (870 (2) (2) 154 (490)